Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
Abstract Severe asthma has a substantial epidemiological impact on children and biological treatments can be an option to take into account, as they target specific molecules and pathways involved in its pathogenesis. Modern medicine is continuously and progressively oriented towards tailored treatm...
Saved in:
Main Authors: | Mattia Giovannini (Author), Francesca Mori (Author), Simona Barni (Author), Maurizio de Martino (Author), Elio Novembre (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2019-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
From the Global Initiative for Asthma report and asthma guidelines to real-life asthma control: is there room for improvement?
by: Elio Novembre, et al.
Published: (2022) -
Case Report: Self-Administration of Omalizumab in an Adolescent With Severe Asthma During SARS-CoV-2 Infection
by: Erika Paladini, et al.
Published: (2021) -
Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
by: Erminia Ridolo, et al.
Published: (2020) -
Venom immunotherapy protocols in the pediatric population: how to choose?
by: Francesca Saretta, et al.
Published: (2023) -
Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma
by: A. G. Tolkushin, et al.
Published: (2019)